共 50 条
- [1] Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell TumorsJOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (21) : 2478 - +Feldman, Darren R.Hu, JamesDorff, Tanya B.Lim, KristinaPatil, SujataWoo, Kaitlin M.Carousso, MaryannHughes, AmandaSheinfeld, JoelBains, ManjitDaneshmand, SiamakKetchens, CharleneBajorin, Dean F.Bosl, George J.Quinn, David I.Motzer, Robert J.
- [2] Paclitaxel, ifosfamide, and cisplatin (TIP) efficacy for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Feldman, Darren RichardHu, JamesDorff, Tanya B.Patil, SujataVan Alstine, Lindsay JoyMomen, LamiaCarousso, MaryannHughes, AmandaSnively-Solomon, JolieKetchens, CharleanSheinfeld, JoelBains, Manjit S.Bajorin, Dean F.Bosl, George J.Motzer, Robert JohnQuinn, David I.
- [3] EFFICACY AND TOLERABILITY OF TIP (PACLITAXEL, IFOSFAMIDE AND CISPLATIN) INCORPORATED INTO INDUCTION CHEMOTHERAPY FOR PATIENTS WITH INTERMEDIATE- OR POOR-RISK METASTATIC GERM CELL TUMORSJOURNAL OF UROLOGY, 2015, 193 (04): : E116 - E116Nishikawa, MasatomoMiyake, HideakiFujisawa, Masato
- [4] Efficacy and tolerability of TIP (paclitaxel, ifosfamide and cisplatin) incorporated into induction chemotherapy for patients with intermediate- or poor-risk metastatic germ cell tumorsMedical Oncology, 2014, 31Masatomo NishikawaHideaki MiyakeMototsugu MuramakiMasato Fujisawa
- [5] Efficacy and tolerability of TIP (paclitaxel, ifosfamide and cisplatin) incorporated into induction chemotherapy for patients with intermediate- or poor-risk metastatic germ cell tumorsMEDICAL ONCOLOGY, 2014, 31 (12) : 1 - 7Nishikawa, MasatomoMiyake, HideakiMuramaki, MototsuguFujisawa, Masato
- [6] Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Feldman, Darren R.Hu, JamesSrinivas, SandyStadler, Walter MichaelCostello, Brian AddisAppleman, Leonard JosephMilowsky, Matthew I.Patil, SujataBromberg, MariaNolan, PatrickDorff, Tanya B.Reuter, Victor E.Al-Ahmadie, HikmatFunt, SamuelBajorin, Dean F.Bosl, George J.Quinn, David I.Motzer, Robert J.
- [7] Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Feldman, Darren R.Hu, James S.Patil, SujataReuter, Victor E.Srinivas, SandyStadler, Walter MichaelCostello, Brian AddisMilowsky, Matthew I.Appleman, Leonard JosephDorff, Tanya B.Bromberg, MariaJoseph, GabriellaFunt, Samuel AaronBajorin, Dean F.Bosl, George J.Quinn, David I.Motzer, Robert J.
- [8] Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumorsUROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2010, 28 (06) : 617 - 623Pectasides, DimitriosPectasides, EiriniPapaxoinis, GeorgeXiros, NikolaosKamposioras, KonstantinosTountas, NikolaosEconomopoulos, Theofanis
- [9] Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)Feldman, Darren RichardHu, JamesDorff, Tanya B.Patil, SujataVan Alstine, Lindsay JoyMomen, LamiaCarousso, MaryannHughes, AmandaSnively-Solomon, JolieKetchens, CharleanSheinfeld, JoelBains, Manjit S.Bajorin, Dean F.Bosl, George J.Motzer, Robert JohnQuinn, David I.
- [10] Testicular Function in Poor-Risk Nonseminomatous Germ Cell Tumors Treated With Methotrexate, Paclitaxel, Ifosfamide, and Cisplatin Combination ChemotherapyJOURNAL OF ANDROLOGY, 2009, 30 (03): : 280 - 286Pectasides, D.Pectasides, E.Papaxoinis, G.Skondra, M.Gerostathou, M.Karageorgopoulou, S.Kamposioras, C.Tountas, N.Koumarianou, A.Psyrri, A.Macheras, A.Economopoulos, T.